Osteoporosis in young adults
Authors:
Zikán Vít
Authors place of work:
Osteocentrum, III. interní klinika 1. LF UK a VFN v Praze
Published in the journal:
Clinical Osteology 2022; 27(4): 135-146
Category:
Summary
Low-trauma fractures in young adults are most often the result of secondary osteoporosis. Less frequently, the cause of fractures or low bone mineral density (BMD) is a monogenic disease with delayed manifestation in adulthood (e.g. osteogenesis imperfecta) or idiopathic osteoporosis. Low BMD alone may reflect a physiologically low peak bone mass in otherwise healthy individuals and does not mean an increased risk of fractures. For clinical practice, it is important to rule out the secondary causes of osteoporosis and other metabolic or cancer induced bone diseases. Treatment should be causal. Anti-osteoporotic treatment is indicated if causal measures are insufficient or cannot be provided, e.g., in osteoporosis induced by chemotherapy or long-term treatment with glucocorticoids.
Keywords:
Young adults – fractures – osteoporosis – low bone mineral density
Zdroje
1. Kanis JA, Delmas P, Burckhardt P et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997; 7(4): 390–406. Dostupné z DOI: <http://dx.doi.org/10.1007/BF01623782>.
2. Sharma M, Dhakad U, Wakhlu A et al. Lean Mass and Disease Activity are the Best Predictors of Bone Mineral Loss in the Premenopausal Women with Rheumatoid Arthritis. Indian J Endocrinol Metab 2018; 22(2): 236–243. Dostupné z DOI: <http://dx.,doi.org/10.4103/ijem.IJEM_665_17>.
3. Rahaman SH, Jyotsna VP, Kandasamy D et al. Bone health in patients with Cushing’s syndrome. Indian J Endocrinol Metab 2018; 22(6): 766–769. Dostupné z DOI: <http://dx.doi.org/10.4103/ijem.IJEM_160_18>.
4. Cairoli E, Eller-Vainicher C, Morlacchi LC et al. Bone involvement in young adults with cystic fbrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int 2019; 30(6): 1255–1263. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–019–04893-z>.
5. Ferrari S, Bianchi ML, Eisman JA et al. IOF Committee of Scientific Advisors Working Group on Osteoporosis Pathophysiology. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int 2 012; 2 3(12): 2 735–2748. Dostupné z DOI: < http://dx.doi.org/10.1007/s00198–012–2030-x>.
6. Hosmer WD, Genant HK, Browner WS. Fractures before menopause: a red flag for physicians. Osteoporos Int 2002; 13(4): 3 37–341. Dostupné z DOI: <http://dx.doi.org/10.1007/s001980200035>.
7. Weaver CM, Gordon CM, Janz KF et al. The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int 2016; 27(4): 1281–1386. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3440–3>.
8. Guilbert ER, Brown JP, Kaunitz AM et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health Contraception 2009; 79(3): 167–177. Dostupné z DOI: <http://dx.doi.org/10.1016/j.contraception.2008.10.016>.
9. Taneja C, Gera S, Kim SM et al. FSH-metabolic circuitry and menopause. J Mol Endocrinol 2019; 63(3): R73-R80. Dostupné z DOI: <http://dx.doi.org/10.1530/JME-19–0152>.
10. Waqas K, Lima Ferreira J et al. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 2021; 1 8(28): 1 00355. Dostupné z DOI: < http://dx.doi.org/10.1016/j.jbo.2021.100355>.
11. Kendler DL, Body JJ, Brandi ML et al. International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease. Bone management in hematologic stem cell transplant recipients. Osteoporos Int 2018; 29(12): 2597–2610. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–018–4669–4>.
12. Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med 2 018; 3 79(26): 2 547–2556. Dostupné z DOI: < http://dx.doi.org/10.1056/NEJMcp1800214>.
13. Hayashi K, Yamamoto M, Murakawa Y et al. Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. Osteoporos Int 2009; 20(11): 1889–1894. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–009–0901–6>.
14. Grizzo FM, Alarcão AC, Dell’ Agnolo CM et al How does women’s bone health recover after lactation? A systematic review and meta-analysis. Osteoporos Int 2020; 31(3): 413–427. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–019–05236–8>.
15. Hardcastle SA. Pregnancy and Lactation Associated Osteoporosis. Calcif Tissue Int 2022; 110(5): 531–545. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–021–00815–6>.
16. Butscheidt S, Delsmann A, Rolvien T et al. Mutational analysis uncovers monogenic bone disorders in women with pregnancy-associated osteoporosis: three novel mutations in LRP5, COL1A1, and COL1A2. Osteoporos Int 2018; 29(7): 1643–1651. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–018–4499–4>.
17. Rozenberg S, Bruyère O, Bergmann P et al. How to manage osteoporosis before the age of 50. Maturitas 2020; 138: 14–25. Dostupné z DOI: <http://dx.doi.org/10.1016/j.maturitas.2020.05.004>.
18. Pepe J, Body JJ, Hadji P et al. Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF. J Clin Endocrinol Metab 2020; 105(8): dgaa306. Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgaa306>.
19. Goetz TG, Nair N, Shiau S et al. In premenopausal women with idiopathic osteoporosis, lower bone formation rate is associated with higher body fat and higher IGF-1.Osteoporos Int. 2022; 33(3): 659–672. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–021–06196–8>.
20. Cohen A, Hostyk J, Baugh EH et al. Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis. B one 2 022; 1 54: 1 16253. Dostupné z DOI: <http://dx.doi.org/116253.10.1016/j.bone.2021.116253>.
21. Stürznickel J, Rolvien T, Delsmann A et al. Clinical Phenotype and Relevance of LRP5 and LRP6 Variants in Patients With Early-Onset Osteoporosis (EOOP). J Bone Miner Res 2021; 36(2): 271–282. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.4197>.
22. Mortier GR, Cohn DH, Cormier-Daire V et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am J Med Genet A . 2 019; 1 79(12): 2 393–2419. Dostupné z DOI: < http://dx.doi.org/10.1002/ajmg.a.61366>.
23. The International Society for Clinical Densitometry (ISCD) official-positions 2019. Dostupné z WWW: <https://www.iscd.org/official-positions/2019-iscd-official-positions-adult>.
24. Pikner R, Palička V, Rosa J et al. Markery kostního obratu u osteoporózy: společné stanovisko k jejich využití Společnosti pro metabolická onemocnění skeletu České lékařské společnosti J. E. Purkyně (SMOS ČLS JEP) a České společnosti klinické biochemie České lékařské společnosti J. E. Purkyně (ČSKB ČLS JEP). Clin Osteol 2020; 25(2): 65–82.
25. Lips P, Cashman KD, Lamberg-Allardt C et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency; a position statement of the European Calcified Tissue Society. Eur J Endocrinol 2019; 180(4): 23–54. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-18–0736>.
26. Vodopivec DM, Silva AM, Garcia-Banigan DC et al. Gender differences in bone mineral density in patients with sporadic primary hyperparathyroidism. Endocrinol Diabetes Metab 2018; 1(4) :e00037. Dostupné z DOI: <http://dx.doi.org/10.1002/edm2.37>.
27. Frei R, Fournier N, Zeitz J et al. [Swiss IBD Cohort Study Group]. Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease: 10-year-follow-up data from the Swiss IBD Cohort Study. J Crohns Colitis 2019; 13(10): 1292–1301. Dostupné z DOI: <http://dx.doi.org/10.1093/ecco-jcc/jjz057>.
28. Shapiro CL, Halabi S, Hars V et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011; 47(5): 683–689. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ejca.2010.11.024>.
29. Kyvernitakis I, Kann PH, Thomasius F et al. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Bone 2018; 114: 109–115. Dostupné z DOI: http://dx.doi.org/10.1016/j.bone.2018.06.007>.
30. Gnant M, Mlineritsch B, Stoeger H et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol 2011; 1 2(7): 6 31–641. Dostupné z DOI: < http://dx.doi.org/10.1016/S1470–2045(11)70122-X>.
31. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2014; (3): CD002010. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD002010.pub4>-
32. Bhardwaj A, Swe KM, Sinha NK et al. Treatment for osteoporosis in people with ß-thalassaemia. Cochrane Database Syst Rev 2016; (3): CD010429. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD010429.pub2>.
33. Yao L, Wang H, Dong W et al. Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease: a meta-analysis. Medicine (Baltimore) 2017; 96(3): e5861. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000005861>.
34. Robinson L, Aldridge V, Clark EM et al. Pharmacological treatment options for low bone mineral density and secondary osteoporosis in anorexia nervosa: a systematic review of the literature. J Psychosom Res 2017; 98: 87–97. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jpsychores.2017.05.011>.
35. Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993; 1 21(2): 2 17–223. Dostupné z DOI: < http://dx.doi.org/10.1006/taap.1993.1148>.
36. Machairiotis N, Ntali G, Kouroutou P et al. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. Horm Mol Biol Clin Investig 2019; 40(2): /j/hmbci.2019.40.issue-2/hmbci-2019–0021/hmbci-2019–0021.xml. Dostupné z DOI: <http://dx.doi.org/10.1515/hmbci-2019–0021>.
37. Langdahl BL. Osteoporosis in premenopausal women. Curr Opin Rheumatol 2017; 29(4): 410–415. Dostupné z DOI: <http://dx.doi.org/10.1097/BOR.0000000000000400>.
38. Tsourdi E, Zillikens MC, Meier C et al. Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. J Clin Endocrinol Metab 2020; dgaa756.Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgaa75>.
39. Boyce RW, Varela A, Chouinard L et al. Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period. Bone 2 014; 6 4: 314–325.Dostupné z DOI: < http://dx.doi.org/10.1016/j.bone.2014.04.002>.
40. Cohen A, Shiau S, Nair N et al. Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial. J Clin Endocrinol Metab 2020; 105(10): e3540–56. Dostupné z DOI: <http://dx.doi.org/10.1210/clinem/dgaa489>.
41. Laroche M, Talibart M, Cormier C et al. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int 2017; 28(11): 3135–3142. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–017–4165–2>.
42. Hong N, Kim JE, Lee SJ et al. Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy-and lactation-associated osteoporosis. Clin Endocrinol (Oxf) 2018; 8 8(5): 6 52–658. Dostupné z DOI: < http://dx.doi.org/10.1111/cen.13557>.
43. Liu ZM, Zhang M, Zong Y et al. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled t rials. P LoS One 2 022; 1 7(5): e 0267706. < http://dx.doi.org/10.1371/journal.pone.0267706>.
44. Saag KG, Shane E, Boonen S et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20): 2028–2039. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa071408>.
45. Ralston SH, Gaston MS. Management of Osteogenesis Imperfecta. Front Endocrinol (Lausanne) 2020; 10: 924. Dostupné z DOI:<http://dx.doi.org/10.3389/fendo.2019.00924>.
46. Bianchi ML, Bishop NJ, Guañabens N, et al. [Rare Bone Disease Action Group of the European Calcified Tissue Society]. Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. Osteoporos Int 2020; 31(8): 1445–1460. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–020–05345–9>.
Štítky
Clinical biochemistry Paediatric gynaecology Paediatric radiology Paediatric rheumatology Endocrinology Gynaecology and obstetrics Internal medicine Orthopaedics General practitioner for adults Radiodiagnostics Rehabilitation Rheumatology Traumatology OsteologyČlánok vyšiel v časopise
Clinical Osteology
2022 Číslo 4
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Memantine Eases Daily Life for Patients and Caregivers
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
Najčítanejšie v tomto čísle
- Osteoporosis in young adults
- Chondrogenic potential of intramembranous skeletal bones
- Circadian rhythms and bone metabolism
- Does hormone replacement therapy have a place in the prevention of osteoporosis?